Senescence-associated heterochromatin focus (SAHF)

Senescence-associated heterochromatin focus (SAHF) is a distinct nuclear substructure forming in senescent mammalian cells, characterized by bright, punctate foci of facultative heterochromatin that repress the expression of proliferation-promoting genes, such as those regulated by E2F transcription factors (e.g., cyclin A)[1][2][4][6][8]. SAHF formation involves the concerted actions of histone chaperones HIRA and ASF1A, and the recruitment of chromatin-modifying proteins including macroH2A, HP1, and HMGA family proteins[2][4][5][6]. SAHF is marked by enrichment of repressive histone modifications, especially H3K9me3, and the exclusion of euchromatin marks[3][4]. Its formation contributes to the irreversible cell cycle arrest observed in senescence and is considered a cellular tumor-suppressive mechanism[1][3]. While SAHF are key features of cellular senescence, they do not represent druggable molecular targets such as receptors, enzymes, or channels, but rather are diagnostic or mechanistic markers of a cellular state[1][6][8]. SAHF can serve as a biomarker for senescence, notably in models of oncogene-induced or replicative cell aging[1][8]. Key points regarding classification: - SAHF are not single proteins, receptors, or enzymes, but large-scale chromatin structures; thus, they are not considered molecular therapeutic targets[1][3][4]. - The presence and integrity of SAHF can reflect the senescent state, which is associated with resistance to malignant transformation and senescence-related pathologies. If you are seeking structured data for drug target mapping or pharmacological profiling, SAHF should not be listed as a molecular target. It is a cytological phenotype and marker of senescence, not a target amenable to direct pharmacological modulation.

Other names

Senescence-associated heterochromatin foci (SAHF)SAHFs